Application 761339
- Type
- BLA
- Sponsor
- REGENERON PHARMACEUTICALS
Purple Book Biologic Products#
| BLA | Proprietary name | Proper name | License type | Status | Latest source |
|---|---|---|---|---|---|
| 761339 | Veopoz | pozelimab-bbfg | 351(a) | Rx | 2026-09-01 |
Application Products#
| Product | Drug | Ingredient | Form | Strength | Reference drug | Reference standard |
|---|---|---|---|---|---|---|
| 001 | VEOPOZ | POZELIMAB-BBFG | INJECTABLE;INJECTION | 400MG/2ML(200MG/ML) | No | No |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| VEOPOZ | POZELIMAB | Regeneron Pharmaceuticals, Inc. | a8d6f10e-9430-450a-a3dd-b538f9b2a308 | 2025-12-04 | Boxed warning, Warnings, Adverse reactions | BLA761339 |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.